Skip to content
Putting patients first: Retail pharmacies—and the patients they serve—are being endangered by PBM Power
This is the fourth in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the […]
BIO’s View
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
Putting patients first: Separating PBM compensation from prices Is critical in reducing patient financial burden
This is the third in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the
Putting patients first: Unchecked step therapy puts PBM profits ahead of patient care
This is the second in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the
Putting patients first: Unchecked step therapy puts PBM profits ahead of patient care Read More »
Putting patients first: Why PBM reform must ensure that middlemen pass along 100% of rebates
This is the first in a series of Bio.News articles looking at the need for pharmacy benefit manager (PBM) reform through the lens of
How utilization management blocks patient access
Insurers and pharmacy benefit managers (PBMs) in search of profits are preventing patients from getting the drugs they need, according to the latest episode
How utilization management blocks patient access Read More »
BIO CEO John F. Crowley calls for innovation in access at Milken Health Summit
As biotech breakthroughs enable remarkable advances in treatment and prevention of disease, we need similar levels of innovation in access, so patients benefit from
BIO CEO John F. Crowley calls for innovation in access at Milken Health Summit Read More »
BIO makes recommendation for new FDA Rare Disease Innovation Hub
The U.S. Food and Drug Administration (FDA) announced the creation of its Rare Disease Innovation Hub in July 2024. With the goal of engaging
BIO makes recommendation for new FDA Rare Disease Innovation Hub Read More »
CMS must address Part D plan abuse of IRA provisions designed to protect patient access
The Biotechnology Innovation Organization (BIO) has once again requested that the Centers for Medicare & Medicaid Services (CMS) take steps to protect patient access,
CMS must address Part D plan abuse of IRA provisions designed to protect patient access Read More »
Skyrocketing 340B program spending must prompt more hospital accountability
The 340B program grew by 24% in 2023, according to new figures from the government’s Health Resources and Services Administration. Sales at discounted prices
Skyrocketing 340B program spending must prompt more hospital accountability Read More »
A family, a firm, and a foundation fighting rare disease join BIO’s podcast
A family battling rare disease, a biopharma startup they’re assisting, and an organization seeking congressional support for new rare disease drugs share their journeys
A family, a firm, and a foundation fighting rare disease join BIO’s podcast Read More »